Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. - Wikidata - wikimedia - TriplyDB

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.

http://www.wikidata.org/entity/Q37789741

about

Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 PCSK9: an emerging target for treatment of hypercholesterolemia.Pharmacological strategies for lowering LDL cholesterol: statins and beyond.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia.Novel strategies for managing dyslipidemia: treatment beyond statins.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Lipid nanoparticle delivery systems for siRNA-based therapeutics.

P2860

Q27003094-F063E9E9-FD77-4F60-ADF9-BB752A0EC2B8 Q34430377-567D9C00-90E1-4961-A8A2-C1E792FD7ED2 Q35767551-6F3637AE-4D4B-442C-AEC0-88400CCBE343 Q35879455-2F725827-EE7A-4101-A9E3-8DF53E9FCCE5 Q37825903-662258E0-C2BC-49AD-B642-6F6042065898 Q37842120-019D499C-B651-497F-ABE3-B85894410A48 Q37880856-901300CA-93BA-4A34-88AC-AA5D9A36D92A Q37981645-B43EA916-1E24-4940-AED5-5D144C6A5B11 Q38001736-8B383C86-C748-4252-980E-C1F7BAC00C31 Q38074335-61720658-9EEE-41FF-B9F8-DF480681C254 Q38786058-5F54307E-15A5-41DD-B37E-A10BB44B97DA Q38846832-AA47F1F4-D02B-44B7-859E-F8299845B073 Q39027758-8362ED04-8F55-46C3-BC0F-D27328E0E1C1

P2860

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.

http://www.wikidata.org/entity/Q37789741

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Strategies for proprotein conv ...... perspective on recent patents.

@en

Strategies for proprotein conv ...... perspective on recent patents.

@nl

type

label

Strategies for proprotein conv ...... perspective on recent patents.

@en

Strategies for proprotein conv ...... perspective on recent patents.

@nl

prefLabel

Strategies for proprotein conv ...... perspective on recent patents.

@en

Strategies for proprotein conv ...... perspective on recent patents.

@nl

P1433

Q37789741-99379CF7-0831-4A7C-AB30-DE495F6ED150

P1476

Q37789741-4A548A1D-7772-4EF4-85F8-EF50F1C3C175

P2093

Q37789741-7AF33E2D-C073-44BC-8979-BE44C797D9C7

Q37789741-943D23DD-286D-4EB9-AF66-ACBBA4D78654

Q37789741-A20FC077-2EAC-40BF-A735-9BF5400A1547

P2860

Q37789741-0484BDB3-8A3D-475E-901C-73F6DDA1079F

Q37789741-09AB01A5-526D-496D-84AA-F70F26C1CC0A

Q37789741-0C9F4EB0-5FC7-481F-B990-04AC2E523DC2

Q37789741-1412D0C1-2F18-4C4E-8354-99F8C926DB20

Q37789741-15DB97B6-DCCF-4D88-91F0-F647BCF9E751

Q37789741-15ED05C2-3141-4A3E-BCFA-3FD21A2A98E8

Q37789741-182B49C9-B59A-45B9-9E3B-557B53B45E87

Q37789741-1A529CBD-452C-46B2-9CCA-696A0887F9F4

Q37789741-1B7C6617-A1CF-46AE-AE17-3E186DEC267F

Q37789741-1BD83C4A-0624-44E3-9FB7-9676EA964009

P304

Q37789741-9951C20D-F996-4638-9B4F-5DD8165BA53C

P31

Q37789741-9A2E32E6-D094-483F-8AFD-994E28500356

P356

Q37789741-ECDB9E97-ABAC-456F-8B10-3977CA3ABCC6

P407

Q37789741-7A4B2B20-CA38-426B-8DD0-349760E33982

P433

Q37789741-1F395600-5293-4D30-ABE0-A3EF80A31A3D

P478

Q37789741-159BB8A8-FC53-44AA-B2A5-23D1C4352216

P50

Q37789741-1A243BC3-1A8A-4169-87F7-47D4B2630924

Q37789741-37637125-C88B-44A3-8D52-E48C4BFE931E

Q37789741-52F4EB58-B7A2-450B-B7D6-9953B35915B6

Q37789741-D4F18D4A-AEC3-4150-B857-0BDCFD1B54DA

P577

Q37789741-FC98B464-11EB-4180-878E-4399D64E4C6D

P698

Q37789741-7CCFE6F9-528D-46E6-8128-DDA70F5866ED

P921

Q37789741-2A6673C5-52F7-4DA7-9628-0ED727FB6951

P356

13543776.2010.518615

P1433

Expert Opinion on Therapeutic Patents

P1476

Strategies for proprotein conv ...... perspective on recent patents.

@en

P2093

Marianne Abifadel

http://www.w3.org/2001/XMLSchema#string

Marie-Elisabeth Samson-Bouma

http://www.w3.org/2001/XMLSchema#string

Matthieu Collin

http://www.w3.org/2001/XMLSchema#string

P2860

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

P304

1547-1571

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543776.2010.518615

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Pierre Rabès

Mathilde Varret

Catherine Boileau

Jihane Pakradouni

P577

2010-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20849207

http://www.w3.org/2001/XMLSchema#string

P921